- Product sales revenue increases 300%

- Net loss narrows significantly

(all figures are in US dollars)

VANCOUVER, Aug. 10 /CNW/ - CRH Medical Corporation (CRM:TSX-V) announced today unaudited results for the three and six months ended June 30, 2009. Highlights of the quarter include:

-   Total revenue for the three months ended June 30, 2009 was $1,853,349
    compared to $1,653,891 for the same period in 2008. Total revenue for
    the six months ended June 30, 2009 was 3,589,239 compared to
    $3,001,333 for the same period in 2008.
-   For the three months ended June 30, 2009 product revenue increased
    225% to $486,971 compared to $149,819 for the same period in 2008.
    For the six months ended June 30, 2009 product revenue increased 300%
    to $815,664 compared to $203,693 for the same period in 2008.
-   The Company recorded a net loss of $363,786 ($0.01 per share) and
    $1,068,794 ($0.02 per share) for the three and six months ended June
    30, 2009 compared to a net loss of $1,097,973 ($0.02 per share) and
    $2,056,711 ($0.05 per share) for the same periods in 2008.
-   As of June 30, 2009 the Company had $1,609,017 in cash and cash
    equivalents and approximately $2.9 million in working capital. On
    April 7, 2009, the Company closed a private placement financing for
    net proceeds of approximately $1.7 million. In April the Company also
    repaid the $350,000 outstanding on its revolving line of credit.

Edward Wright, Chief Executive Officer stated, "We believe CRH Medical Corporation is affecting a "Paradigm Shift" in the treatment of hemorrhoids through physicians utilizing its proprietary CRH O'Regan System. Our product sales revenue continues to build and we have trained only 252 of the more than 8,000 gastroenterologist in the United States. The continued growth of our Partnership Program in combination with our cost saving initiatives has enabled CRH to dramatically decrease our net loss which is in line with our goal of achieving profitability in 2010."

The Company's June 30, 2008 financial report will be available on www.sedar.com

About CRH Medical Corporation:

CRH Medical Corporation specializes in the treatment of hemorrhoids utilizing its proven treatment protocol and patented proprietary technology. CRH's single use, disposable, hemorrhoid technology is safe and highly effective in treating hemorrhoid grades I - IV. CRH Medical employs two commercialization strategies: First, it operates Centers for Colorectal Health facilities in the United States specializing in the treatment of hemorrhoids and fissures, and colon cancer screening. In addition CRH distributes its hemorrhoid banding technology, treatment protocols, operational and marketing expertise as a complete, "turn key" package directly to its partner physicians.